Partner Perspectives
Benin
Dr. William Houndjo
“Community engagement and social and behavior change activities will enable the individual to overcome known barriers to practicing a behavior. ”
— Dr. William Houndjo, Head of chemoprevention, department, nmcp
Cameroon
Dr. Manaouda Malachie
"Thanks to the technical support of ACMS and under Unitaid funding, we will compare the national five-dose strategy with an eight-dose strategy called "Plus Project" which will be piloted in six districts of the Center Region."
— DR. MANAOUDA MALACHIE, MINISTER OF PUBLIC HEALTH, CAMEROON
Cote d’Ivoire
Mr. Bepha N'DRI
"We left the workshop recreated and enriched, without having felt too heavy a weight from the work done."
— Mr. Bepha N'Dri, Capacity building officer, arsip
Mozambique
Mrs. Albertina Chihale
Mrs. Albertina Chihale, National Directorate of Public Health/ National Malaria Control Program (NMCP) of Ministry Health Mozambique participated in the training of trainers (ToT) on Community Engagement (CE) and shared her impressions on this activity.
According to her, “The involvement of the national party in the workshop was important because it allows us to acquire an in-depth knowledge of the project in general as well as the involvement of the community in particular. This was important because for the success of this project, the government and PSI must work together from start to finish. Moreover, when the strategy is approved, the Ministry of Health will have the capacity to implement it.‘’
“For the success of this project, the government and PSI must work together from start to finish.”
— Mrs. Albertina Chihale, nATIONAL DIRECTORATE OF PUBLIC HEALTH, NMCP
CENTRE FOR MEDICAL PARASITOLOGY (CMP) UNIVERSITY OF COPENHAGEN (UCPH) Michael Alifrangis
CMP is an independent research center at the UCPH that for the last 30 years has conducted malaria research and as well been much involved in research capacity development in many countries of sub-Saharan Africa. “Our group is within the DRUGs team of CMP and our research on antimalarial drugs has included testing chemopreventive treatment strategies, such as IPTp, SMC & IPTi/PMC. A key question, particularly with sulfadoxine-pyrimethamine (SP) in Africa, is whether antimalarial drug resistance may constitute a challenge to preventive efficacy, because resistance levels vary so widely between countries and because they are continually changing. In the Genotyping work for the Plus Project, a partnership led by Cally Roper at LSHTM, we will be mapping the level of (molecular) SP resistance in close collaboration with the partner teams in each of the 7 countries. Specifically, our goal is to map SP resistance to district level by analyzing malaria positive samples collected from patients and genotyping the mutations that cause resistance. We will be using Illumina next generation sequencing and the approach developed by our team can analyze some 12 resistance gene targets in 2450 samples in a single run. We are excited to be part of this project, providing molecular data to inform policy. It is to the best of our knowledge the first-time molecular sequence data will directly feed into the design and tailoring of the chemo-preventive strategy of individual countries.”
"We are excited to be part of this project, providing molecular data to inform policy. It is to the best of our knowledge the first-time molecular sequence data will directly feed into the design and tailoring of the chemo-preventive strategy of individual countries."